Le Lézard
Classified in: Health, Covid-19 virus
Subject: TDS

Chinese biotech firm Vazyme to showcase full range of COVID-19 Testing Solutions at Medlab


DUBAI, UAE, June 14, 2021 /PRNewswire/ -- Chinese biotechnology company Vazyme will showcase a rich lineup of products at the 2021 Medlab Middle East, a leading medical laboratory exhibition co-located with Arab Health. The live in-person event is scheduled to take place from 21 to 24 June, 2021 at Dubai World Trade Centre. The product series, including the Automatic Nucleic Acid Extraction Instrument, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen Detection Kit (Colloidal Gold-Based), the Post-vaccination Antibody Detection Kit and Quantum Dot Fluorescence Immune analyzers, will be on display at Booth No. Z5.D40.

Vazyme to showcase full range of Covid-19 diagnostic and treatment solutions at 2021 Medlab Middle East

Medlab has become a world-famous laboratory exhibition and a globally-recognized professional IVD expo with international stature. Last year alone, the event attracted more than 23,000 medical laboratory, healthcare and trade professionals from over 140 countries and regions worldwide. This year's exhibition will bring together more than 650 top firms from over 40 countries and regions.

As one of the few research and development (R&D)-focused innovative producers in China that has capabilities in developing upstream technologies in-house and manufacturing finished products, Vazyme plans to exhibit many of its key offerings at the event, including COVID-19 Testing Solutions, alongside its proprietary in vitro diagnostic instruments. This lineup of exhibits is expected to play an important role in promoting health maintenance and preventing and controlling any further spread of COVID-19. 

Highlights of Vazyme's key products will include:

COVID-19 detection kits:

Research reagents:

With its strong competence in R&D and extensive technology expertise, Vazyme has been committed to preventing and controlling the spread of COVID-19. After the outbreak of the disease, the company quickly completed the research and development of raw materials for nucleic acid diagnostic reagents and greatly improved the sensitivity and specificity of the detection kits while providing reagent manufacturers with raw materials that can be used to produce more than 500 million diagnostic kits. Additionally, the R&D team has successfully developed an antibody detection kit that is based on the firm's key generic technology platform and displays results within ten minutes. To date, Vazyme has exported more than 30 million detection reagents globally. The firm has also introduced an antigen test kit that further improves the detection efficiency before rolling out neutralizing and RBD Protein IgG detection kits that are used to evaluate the efficacy of vaccines that are already available in the market and assist in developing new vaccines with higher efficacy.

Vazyme has made great contributions to the prevention and control of the pandemic. In particular, the company has offered COVID-19 Testing Solutions to 19 countries and regions worldwide after receiving approval from the respective oversight authorities, including, among others, the UK Medicines and Healthcare Products Regulatory Agency (MHRA), Russia's GOST, the Brazilian Health Regulatory Agency (ANVISA) and the Indonesian Food and Drug Authority.

To further expand its business in world markets, Vazyme plans to further broaden its in vitro diagnostic portfolio by increasing investment in the development of innovative solutions.

Vazyme Booth Information

Date (Live Exhibition): June 21-24, 2021
Location: Dubai World Trade Centre, UAE
Booth No.: Z5.D40
Date (Online Exhibition): 23 May - 22 July, 2021

About Nanjing Vazyme Biotech Co., Ltd

Founded in 2012, Vazyme is one of the few R&D-focused innovative biotechnology firms in China that has capabilities in developing upstream technologies in-house and manufacturing finished products. With an ongoing commitment to innovation and based on its proprietary key generic technology platform, the company has built a business network spanning biological research, in vitro diagnosis and biomedicine. Currently, the firm has a portfolio of over 200 kinds of genetic engineering recombinases, more than 1,000 kinds of high-performance antigens, monoclonal antibodies and other key raw materials, in addition to over 500 finished products. Besides, Vazyme has developed eight series of proprietary POCT diagnostic reagents and related control materials covering cardiovascular and cerebrovascular diseases, inflammation, prepotency, gastric functions, autoimmunity, renal functions, chronic disease management as well as respiratory diseases.

For more information, please visit Vazyme's official website at http://www.vazyme.com.

Photo - https://mma.prnewswire.com/media/1530533/1.jpg

 


These press releases may also interest you

at 10:45
The "U.S. Augmented and Virtual Reality Headset Market - A Country Analysis: Focus on Application, Product, and Country - Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering. The U.S. augmented and virtual...

at 10:20
The "Global Functional Milk Market - Outlook & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering. The global functional milk market was valued at $27.00 billion in 2023 and is expected to reach a value of $41.74 billion...

at 10:15
Jazz PharmaceuticalsBy Liz HendersonLiz Henderson, Sr. Vice President Technical Operations at Jazz Pharmaceuticals discusses pioneering innovation in oncology and the importance of the manufacturing infrastructure to help achieve drug development...

at 10:10
Allied Market Research published a report, titled, "Real Estate Investment Trust Market by Type (Equity REITs, Mortgage REITs, and Hybrid REITs), and Application (Industrial, Commercial, and Residential): Global Opportunity Analysis and Industry...

at 10:05
Mayfair Gold Corp. ("Mayfair" or the "Company") today announced that it has received a shareholder meeting requisition notice pursuant to section 167 of the Business Corporations Act (British Columbia) (the "Requisition") dated March 27, 2024 from...

at 09:50
The "Thailand Construction Equipment Rental Market - Strategic Assessment & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Thailand construction equipment rental market is expected to reach a value of $428.7...



News published on and distributed by: